Venous Thromboembolism Prophylaxis & Management

ABPN Neurocritical Care Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Neurologic Examination & Coma Assessment in the ICU

Current Examination, Blueprint & Preparation Neurologic Examination in Critically Ill Patients Coma Evaluation & Consciousness Alterations Delirium & Toxic-Metabolic Encephalopathy in the ICU

2 Chapter 2: Cerebral Physiology & Intracranial Dynamics

Cerebral Blood Flow, Metabolism & Autoregulation Intracranial Pressure & Compliance Cerebral Edema & Herniation Syndromes

3 Chapter 3: Intracranial Hypertension & Cerebral Perfusion Management

Tiered ICP Management Protocols Hyperosmolar Therapy & Fluid Management Advanced & Refractory ICP Interventions

4 Chapter 4: Airway, Mechanical Ventilation & Pulmonary ICU Management

Emergency Airway Management & Neuro-Intubation Mechanical Ventilation Strategies in Acute Brain Injury Tracheostomy & Ventilator Weaning in Neurocritical Care Pulmonary Complications in the Neuro-ICU Obstructive Lung Disease, Pulmonary Hypertension & Bronchoscopy

5 Chapter 5: Hemodynamics, Shock & Cardiovascular Management

Hemodynamic Monitoring & Blood Pressure Targets Vasoactive Agents: Inotropes, Vasopressors & Antihypertensives Cardiac Complications of Brain Injury

6 Chapter 6: Neuropharmacology, Analgesia & Sedation

ICU Sedation & Analgesia Neuromuscular Blockade & Monitoring Propofol Infusion Syndrome & Drug Toxicities Antiseizure Drug Pharmacology in the ICU

7 Bleeding, Thrombosis & Hematologic Emergencies

Warfarin & Heparin Reversal Direct Oral Anticoagulant (DOAC) Reversal Antiplatelet Management & Platelet Dysfunction Venous Thromboembolism Prophylaxis & Management Transfusion, Coagulopathy, TMA & Cellular-Therapy Neurotoxicity

8 Chapter 8: Systemic ICU Care, Fluids, Electrolytes & Endocrine

Hyponatremia & Osmoregulation: SIADH vs Cerebral Salt Wasting Diabetes Insipidus, Hypernatremia & Endocrine Crises Critical Care Prophylaxis, Nutrition & Infection Prevention

9 Systemic Trauma & Environmental Injury

Polytrauma, Chest Injury & Abdominal Hemorrhage Burns, Electrical Injury & Hanging

10 Cardiac Emergencies & Mechanical Support

IABP, Ventricular Devices & ECMO Acute Coronary, Valvular, Rhythm & Aortic Emergencies

11 Kidney Injury, Acid–Base & Renal Replacement

Acute Kidney Injury & Renal Drug Clearance Acid–Base Disorders, Electrolytes & Renal Replacement

12 Systemic Infection & Endocrine Emergencies

Sepsis, Endocarditis & Antimicrobial Principles Thyroid, Adrenal & Dysglycemic Emergencies

13 Gastrointestinal & Hepatic Emergencies

Acute Abdomen, GI Bleeding & Abdominal Compartment Syndrome Acute Liver Failure, Cirrhosis & Hepatic Drug Effects

14 Chapter 9: Neuroimaging in the Neuro-ICU

Non-Contrast CT & CT Angiography CT Perfusion & Advanced Perfusion Imaging Magnetic Resonance Imaging in Critical Illness

15 Chapter 10: Electrophysiology & Neuromonitoring

Continuous EEG & ACNS Standardized Critical Care Terminology Invasive Neuromonitoring: ICP & External Ventricular Drains Multimodal Monitoring: PbtO2, Microdialysis & Transcranial Doppler

16 Angiography, Electrodiagnosis & CSF Analysis

Conventional Angiography & Cranial–Spinal Shunts EMG, Nerve Conduction & Acute Muscle Disease CSF Analysis: Infection, Inflammation & Hemorrhage

17 Chapter 11: Bedside Procedures, Ultrasound & Death by Neurologic Criteria

Critical Care Procedural Skills Critical Care Ultrasound & Echocardiography Determination of Death by Neurologic Criteria

18 Chapter 12: Acute Ischemic Stroke & Reperfusion Therapies

Acute Ischemic Stroke Management & Thrombolysis Endovascular Thrombectomy & Large Vessel Occlusion Malignant Hemispheric & Cerebellar Infarction

19 Chapter 13: Spontaneous Intracerebral Hemorrhage & Intraventricular Hemorrhage

Acute Intraparenchymal Hemorrhage Management Intraventricular Hemorrhage & Hydrocephalus Surgical Evacuation & Minimally Invasive Surgery in ICH

20 Chapter 14: Aneurysmal Subarachnoid Hemorrhage & Delayed Cerebral Ischemia

Aneurysmal Subarachnoid Hemorrhage: Acute Resuscitation & Securing Delayed Cerebral Ischemia & Cerebral Vasospasm Non-Aneurysmal Subarachnoid Hemorrhage & Vascular Malformations

21 Venous, Spinal & Traumatic Vascular Disease

Cerebral Venous Thrombosis & Spinal Cord Infarction Traumatic Dissection, Carotid–Cavernous Fistula & Penetrating Injury

22 Chapter 15: Traumatic Brain & Spinal Cord Injury

Severe Traumatic Brain Injury & Contusions Acute Traumatic Spinal Cord Injury & Neurogenic Shock Spine Trauma, Fractures & Cord Syndromes

23 Chapter 16: Status Epilepticus, Seizures & Neuromuscular Emergencies

Status Epilepticus: Convulsive & Non-Convulsive Refractory & Super-Refractory Status Epilepticus Acute Neuromuscular Respiratory Failure

24 Chapter 17: Post-Cardiac Arrest Care, CNS Infections & Encephalitis

Targeted Temperature Management & Post-Cardiac Arrest Care Post-Cardiac Arrest Neuroprognostication Acute CNS Infections, Encephalitis & Inflammatory Emergencies

25 Neuroinflammation & Neurooncology

Fulminant Demyelination & Autoimmune Encephalitis Brain, Spinal & Leptomeningeal Cancer Emergencies

26 Pregnancy, Transplantation & Pediatric Care

Pregnancy, Postpartum & Post-Transplant Neurologic Care Pediatric Neurocritical Care

27 Chapter 18: Neurosurgical & Perioperative Emergencies

Postoperative Neurosurgical Complications Device Complications: EVDs, Shunts & ICP Monitors Cerebral Hyperperfusion Syndrome & Post-Interventional Emergencies

28 Chapter 19: Ethics, Palliative Care & Organ Donation in the Neuro-ICU

Communication, Surrogate Decision-Making & Conflict Resolution Neuroprognostication Ethics, Withdrawal of Life Support & Palliative Care Organ Donation & Management of the Deceased Donor

Venous Thromboembolism Prophylaxis & Management

Key Takeaways Explain This Topic AI

Intermittent pneumatic compression begins early in nonambulatory ICH patients; graduated compression stockings alone do not provide the same benefit.

Low-dose UFH or LMWH after ICH requires clinical and imaging assessment; initiation around 24–48 hours may be reasonable in selected stable patients.

Therapeutic anticoagulation for acute VTE after ICH is individualized; a retrievable filter can be a bridge when anticoagulation is temporarily unsafe.

Restarting long-term anticoagulation depends on the indication and bleeding risk; atrial fibrillation and a mechanical valve do not share one fixed timetable.

Last updated: October 2026

Venous Thromboembolism Prophylaxis & Management

Venous thromboembolism ( V T E VTE V TE ), encompassing deep vein thrombosis ( D V T DVT D V T ) and pulmonary embolism ( P E PE PE ), represents one of the most common and preventable causes of secondary morbidity and mortality in neurocritical care. Without thromboprophylaxis, the incidence of hospital-acquired D V T DVT D V T in acute stroke, traumatic brain injury ( T B I TBI TB I ), and spinal cord injury cohorts exceeds 50 % to 75 % 50\%\text{ to }75\% 50% to 75% . Pulmonary embolism accounts for up to 10 % to 15 % 10\%\text{ to }15\% 10% to 15% of all in-hospital deaths following intracerebral hemorrhage. Managing V T E VTE V TE in neuro-ICU patients requires walking a precarious tightrope between preventing fatal pulmonary emboli and avoiding catastrophic secondary intracranial re-bleeding.

VTE Epidemiology & Pathophysiology in Neurocritical Care

Neurocritical care patients fulfill all three arms of Virchow's Triad with unparalleled severity: Virchow's Triad in Acute Neurological Injury

├── Venous Stasis: Flaccid hemiplegia, loss of calf muscle pump, coma, prolonged bed rest

├── Hypercoagulability: Systemic inflammatory cascade, release of brain tissue factor, elevated Factor VIII & fibrinogen

└── Endothelial Injury: Femoral central venous lines, polytrauma, immobilization-induced shear changes

Venous Stasis: Dense motor hemiplegia, paraplegia, therapeutic neuromuscular blockade, high-dose analgosedation, and coma eliminate voluntary muscle contraction. Loss of the peripheral calf-muscle pump promotes marked venous pooling and stasis in the deep sinusoids of the lower extremities.

Hypercoagulability: The injured brain parenchyma contains the highest concentration of tissue factor (Factor III) of any organ in the human body. Disruption of the blood-brain barrier releases tissue factor directly into the systemic circulation, triggering widespread, low-grade intravascular thrombin generation. Concurrently, acute phase reactants such as fibrinogen and Factor VIII spike, while endogenous fibrinolysis is suppressed.

Endothelial Injury: Prolonged femoral central venous catheterization, invasive arterial monitoring, and polytrauma inflict direct mechanical endothelial denudation, exposing pro-thrombotic subendothelial matrix.

Mechanical Thromboprophylaxis: IPC vs. Compression Stockings

Mechanical thromboprophylaxis provides hemostatically neutral protection against D V T DVT D V T and must be instituted immediately upon presentation in every neuro-ICU patient unless absolute local contraindications (such as severe peripheral artery disease, lower extremity burns, or acute circumferential ulcers) exist.

Intermittent Pneumatic Compression (IPC) & The CLOTS 3 Trial

Intermittent pneumatic compression devices apply sequential, circumferential pneumatic pressure bladders from the ankle to the upper calf, inflating to 45 to 50 mmHg 45\text{ to }50\text{ mmHg} 45 to 50 mmHg at regular intervals:

Physiologic Effects: IPC empties lower extremity venous reservoirs, augments peak venous blood flow velocity, eliminates stasis, and stimulates endogenous vascular endothelial release of tissue plasminogen activator ( t P A tPA tP A ) and endothelial nitric oxide synthase ( e N O S eNOS e NOS ), promoting local endogenous fibrinolysis.

The CLOTS 3 Trial (Lancet 2013): A multicenter randomized trial of 2,876 immobile acute stroke patients comparing routine IPC versus no IPC. Patients allocated to IPC experienced a significant reduction in proximal deep vein thrombosis ( 8.5 % 8.5\% 8.5% vs. 12.1 % 12.1\% 12.1% , adjusted odds ratio 0.69 0.69 0.69 , 95 % 95\% 95% CI 0.55 – 0.86 0.55\text{--}0.86 0.55 – 0.86 , p = 0.009 p = 0.009 p = 0.009 ). Crucially, IPC was associated with a statistically significant improvement in 6 -month 6\text{-month} 6 -month survival ( p = 0.042 p = 0.042 p = 0.042 ) .

Evidence: CLOTS 1 found no benefit of thigh-length stockings versus avoidance. CLOTS 2 compared thigh-length with below-knee stockings and favored thigh-length for proximal DVT; it did not show that both were equivalent to no stockings. Guidelines favor IPC rather than stockings alone for immobile ICH patients.

Timing of Pharmacologic Thromboprophylaxis after Intracranial Hemorrhage

While mechanical prophylaxis is vital, IPC alone is insufficient to prevent all thromboembolic events. The pivotal question is when it becomes safe to initiate low-dose chemoprophylaxis without inciting hematoma expansion.

Spontaneous Intracerebral Hemorrhage (sICH)

The Golden 24 -to- 48 -Hour 24\text{-to-}48\text{-Hour} 24 -to- 48 -Hour Rule: Most spontaneous intracerebral hematoma expansion occurs within the first 24 hours 24\text{ hours} 24 hours post-ictus. Prospective registry data and randomized feasibility trials demonstrate that low-dose chemoprophylaxis is safe when initiated at 24 to 48 hours 24\text{ to }48\text{ hours} 24 to 48 hours after symptom onset.

Prerequisite Stability Scan: A non-contrast head CT must be obtained at 24 hours 24\text{ hours} 24 hours to verify radiographic hematoma stability . If the repeat CT shows no expansion and no new intraventricular extravasation, pharmacologic prophylaxis should be initiated.

Recommended Agents: Subcutaneous low-molecular-weight heparin (enoxaparin 30 mg 30\text{ mg} 30 mg subcutaneously every 12 hours 12\text{ hours} 12 hours or 40 mg 40\text{ mg} 40 mg once daily) or low-dose unfractionated heparin ( 5000 units 5000\text{ units} 5000 units subcutaneously every 8 hours 8\text{ hours} 8 hours ) . Low-molecular-weight heparin is preferred over UFH because it provides superior anti-Xa bioavailability, more predictable anticoagulation, and lower rates of heparin-induced thrombocytopenia ( H I T HIT H I T ). In patients with severe renal insufficiency ( C r C l < 30 mL/min CrCl < 30\text{ mL/min} C r Cl < 30 mL/min ), dose-adjusted UFH is preferred due to lack of renal accumulation.

Traumatic Brain Injury (TBI)

Under Brain Trauma Foundation ( B T F BTF BTF ) and Western Trauma Association ( W T A WTA W T A ) consensus protocols, low-dose L M W H LMWH L M W H or U F H UFH U F H is safe to initiate within 24 to 48 hours 24\text{ to }48\text{ hours} 24 to 48 hours of injury or admission, provided a scheduled repeat head CT at 24 hours 24\text{ hours} 24 hours confirms stability of cerebral contusions, traumatic subarachnoid hemorrhage, or subdural hematomas.

Aneurysmal Subarachnoid Hemorrhage (aSAH)

Post-Securing Initiation: In aneurysmal S A H SAH S A H , pharmacologic thromboprophylaxis is strictly contraindicated while an aneurysm remains unsecured due to the catastrophic mortality of re-rupture ( > 70 % > 70\% > 70% ). Once the aneurysm is definitively secured via endovascular coiling or surgical clipping , subcutaneous chemoprophylaxis should be initiated 24 hours 24\text{ hours} 24 hours post-procedure .

External Ventricular Drains (EVD): The presence of an external ventricular drain is not a contraindication to prophylactic low-dose L M W H / U F H LMWH/UFH L M W H / U F H . Multiple prospective studies have established that low-dose chemoprophylaxis does not increase clinically meaningful catheter-tract hemorrhages during drain maintenance or routine removal.

Post-Craniotomy

Following elective or trauma-related craniotomy, subcutaneous heparin or enoxaparin is initiated at 24 to 48 hours 24\text{ to }48\text{ hours} 24 to 48 hours postoperatively , once postoperative neuroimaging confirms complete hemostasis and absence of extra-axial hematoma accumulation.

Clinical Condition Mechanical Prophylaxis Stability Requirement Pharmacologic Initiation Window Preferred Regimen

Spontaneous ICH IPC from admission Non-contrast CT at 24 h 24\text{ h} 24 h stable 24 to 48 hours 24\text{ to }48\text{ hours} 24 to 48 hours post-ictus Enoxaparin 30 mg 30\text{ mg} 30 mg SC q12h (or UFH 5000 u 5000\text{ u} 5000 u q8h)

Traumatic Brain Injury IPC from admission Follow-up CT at 24 h 24\text{ h} 24 h stable 24 to 48 hours 24\text{ to }48\text{ hours} 24 to 48 hours post-injury Enoxaparin 30 mg 30\text{ mg} 30 mg SC q12h

Aneurysmal SAH IPC from admission Aneurysm secured 24 hours 24\text{ hours} 24 hours after coiling/clipping Enoxaparin 40 mg 40\text{ mg} 40 mg SC q24h or UFH 5000 u 5000\text{ u} 5000 u q8h

Post-Craniotomy IPC from admission Post-op CT confirming hemostasis 24 to 48 hours 24\text{ to }48\text{ hours} 24 to 48 hours post-op UFH 5000 u 5000\text{ u} 5000 u SC q8h or Enoxaparin 30 mg 30\text{ mg} 30 mg q12h

Management of Acute VTE in the Acute ICH Window

When acute proximal DVT or PE occurs after recent ICH, weigh hemorrhage stability, time since onset, clot severity, and competing risks. AHA/ASA states that delaying therapeutic UFH or LMWH for one to two weeks might be considered in selected ICH patients. This is not an absolute ban on all earlier anticoagulation or one universal timing rule. A retrievable IVC filter can bridge a proximal DVT when anticoagulation is temporarily unsuitable.

Inferior Vena Cava (IVC) Filters

In this clinical scenario, placement of a retrievable Inferior Vena Cava (IVC) filter is indicated as a temporary mechanical sieve to capture migrating macro-emboli and prevent fatal saddle pulmonary emboli:

Filtration Mechanics: The filter is deployed infra-renally via femoral or internal jugular percutaneous access. It does not treat, dissolve, or halt local extension of the underlying lower extremity thrombus; it purely functions as a mechanical trap.

Mandatory Filter Retrieval Protocol: Retrievable filters must be systematically tracked in an institutional registry. Once the patient has passed the high-risk intracranial hemorrhage window and therapeutic anticoagulation can be safely initiated, the filter should be retrieved to prevent long-term filter thrombosis, lower-extremity venous stasis syndrome, filter migration, or caval perforation.

Warning

Prophylactic IVC filter placement (inserting an IVC filter in the absence of documented DVT/PE) is not recommended in neurocritical care. Routine prophylactic filters increase secondary deep vein thrombosis without improving survival. IVC filters are reserved strictly for documented proximal DVT/PE in the presence of an absolute contraindication to anticoagulation.

Resuming Therapeutic Anticoagulation

Treating acute VTE, restarting therapy for a mechanical valve, and restarting anticoagulation for atrial fibrillation are different decisions. For nonvalvular AF after spontaneous ICH, AHA/ASA suggests that initiation around seven to eight weeks may be considered after individual benefit–risk assessment. Mechanical valves or other exceptionally high thrombotic risks may support earlier resumption. Hemorrhage location, suspected CAA, imaging, blood pressure, and procedural plans influence the balance. Left atrial appendage closure may be considered in selected AF patients unable to take anticoagulation; it is not automatically preferred for every lobar ICH.

When anticoagulation is restarted, select agent, dose, and monitoring with the responsible teams. Repeat examination and imaging as indicated. An IVC filter does not treat the original clot and should have a retrieval plan once it is no longer needed.